• Herantis Pharma announces positive interim data from Lymfactin study in secondary lymphedema

    April 16, 2018

    Herantis Pharma PlcCompany release 16 Apr 2018 at 9:00 am Herantis Pharma Plc (“Herantis”) announced today positive results from a safety evaluation in the ongoing Phase 1 clinical study assessing the safety and tolerability of the company’s investigational gene therapy product Lymfactin® in the treatment of secondary lymphedema. Based on data from all 15 patients recruited, the study’s Data Monitoring Committee (“DMC”) of independent experts concluded that Lymfactin® continues to appear safe and well tolerated. No dose limiting toxicities were observed. The safety evaluation wa

    Read More
  • CellAegis Announces First Patients Enrolled in U.S. Shield Pivotal Clinical Trial

    April 10, 2018

    TORONTO, Canada, April 10, 2018 (GLOBE NEWSWIRE) – CellAegis Devices Inc. (“CellAegis” or the “Company”), a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for acute and chronic cardiovascular conditions, today announced enrollment of the first patients in a U.S. clinical trial (“SHIELD”) of its autoRIC® device. The autoRIC® device automatically delivers remote ischemic conditioning (“RIC”) to provide a non-invasive, cardio-protective therapy shown to reduce heart damage during heart attacks and certain cardio

    Read More
  • Broadview Ventures 2017 Annual Report

    March 20, 2018

    Broadview Ventures 2017 Annual Report

    Read More
  • Acesion Pharma Commences Phase 1 Study in Atrial Fibrillation

    March 12, 2018

    COPENHAGEN, Denmark— 12 March 2018: Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces it has commenced the clinical study for its lead compound AP30663. Acesion is developing a portfolio of drugs addressing both paroxysmal (acute) and persistent AF. Link to Press Release

    Read More
  • Vectorious closes B round, setting stage for trials of heart-monitoring implant

    March 8, 2018

    Vectorious Medical Technologies has raised cash to trial an implant for monitoring left atrial pressure in congestive heart failure patients, Globes reports. The series B round will fund a device the Israel-based company sees improving outcomes and cutting costs in an indication dogged by stubbornly high mortality rates. Vectorious’ answer to the solidly double-digit one-year mortality rate of heart failure patients is a miniature implant. Following delivery via a minimally invasive procedure, the device gathers data on blood flow in the left atrium. The data are transmitted via what Ve

    Read More
  • Acesion Pharma Receives Approval for Phase I Study in Atrial Fibrillation

    February 8, 2018

    COPENHAGEN, Denmark— 8 February 2018: Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces today it has received approval to commence its first clinical study for its lead compound AP30663. The phase 1 study in healthy subjects will be conducted at the Centre for Human Drug Research (CHDR) in the Netherlands and is due to start in March 2018. Acesion also announces the appointment of internationally renowned AF experts as scientific advisors. Link to Press Release

    Read More
  • ZZ Biotech Announces Preliminary Phase 2 Stroke Trial Results

    January 29, 2018

    ZZ Biotech Announces Preliminary Phase 2 Stroke Trial Results with 3K3A-APC Houston, TX, USA, January 29, 2018 / B3C newswire / -- ZZ Biotech today announced that preliminary results of RHAPSODY, the company’s Phase 2 clinical trial in acute ischemic stroke patients, were presented at the 2018 International Stroke Conference in Los Angeles. The placebo-controlled dose-escalation trial was designed to establish a maximally tolerated dose (MTD) of 3K3A-APC in patients with acute ischemic stroke treated with intravenous tPA, intra-arterial thrombectomy, or both. A secondary endpoint was to

    Read More
  • 480 Biomedical’s Novel Technology Featured in Nature Materials

    November 21, 2017

    480 Biomedical develops new technology which imparts metal-like strength on bioresorbable polymers WATERTOWN, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- 480 Biomedical, a clinical-stage life science company committed to transforming the lives of patients with chronic diseases, announced a publication in Nature Materials highlighting the novel mechanical properties of the company’s fully bioresorbable polymeric implant technology. As described in Nature Materials, the 480 Biomedical implant has been demonstrated in pre-clinical studies to possess resistive strength similar to metal, while m

    Read More
  • Boston Scientific Announces Agreement to Acquire Apama Medical

    October 10, 2017

    Acquisition to Strengthen Company's Electrophysiology Portfolio and Expand into "Single-Shot" Balloon Pulmonary Vein Isolation Treatments for Patients with Atrial Fibrillation Oct 2, 2017 MARLBOROUGH, Mass., Oct. 2, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Apama Medical Inc., a privately-held company that is developing the Apama Radiofrequency (RF) Balloon Catheter System for the treatment of atrial fibrillation (AF). The transaction consists of $175 million in cash up-front and a maximum of $125 million in cont

    Read More
  • New Options in Wireless Remote Patient Monitoring

    May 24, 2017

    Interview with Michael Mazzini, MD Author(s): Interview by Jodie Elrod Issue Number: Volume 17 - Issue 5 - May 2017 Dr. Michael Mazzini is with North Suburban Cardiology Associates in Stoneham, Massachusetts. In this interview, we speak with him about his use of the MoMe® Kardia wireless remote patient monitoring system (InfoBionic), a 3-in-1 device that acquires and stores ECG and motion data, and transmits it through the company’s cloud-based system for analysis.   Press Release

    Read More